Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Medtronic
Merck
Moodys
Dow

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

NORPACE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Norpace, and when can generic versions of Norpace launch?

Norpace is a drug marketed by Gd Searle Llc and is included in two NDAs.

The generic ingredient in NORPACE is disopyramide phosphate. There are nineteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.

Drug patent expirations by year for NORPACE
Drug Prices for NORPACE

See drug prices for NORPACE

Recent Clinical Trials for NORPACE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 3
MedtronicPhase 3

See all NORPACE clinical trials

Pharmacology for NORPACE
Drug ClassAntiarrhythmic
Synonyms for NORPACE
(+-)-alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
(R)-4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide phosphate
2-(1-(Ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium phosphate
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (+-)-, phosphate (1:1)
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate (1:1)
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate (9CI)
2-Pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-, phosphate
22059-60-5
3737-09-5 (Parent)
4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide; phosphoric acid
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide,phosphoric acid
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide; phosphoric acid
a-[2-(diisopropylamino)ethyl]-a-phenyl-2-pyridineacetamide phosphate
AC1L1KKM
AC1Q6RT0
AC1Q7DLA
ACM22059605
alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
alpha-(2-Diisopropylaminoethyl)-alpha-phenyl-2-pyridineacetamide phosphate
API0002424
C07740
C21H29N3O.H3O4P
C21H32N3O5P
CCG-40209
CHEBI:4658
CHEMBL1201020
CPD000058438
D 6035
D00637
Disopyramid phosphate
DISOPYRAMIDE PHOSPHATE
Disopyramide phosphate (JAN/USP)
Disopyramide phosphate [USAN:BAN:JAN]
Disopyramide phosphate [USAN:USP:BAN:JAN]
DISOPYRAMIDE PHOSPHATE SALT
Disopyramide phosphate, European Pharmacopoeia (EP) Reference Standard
Disopyramide phosphate, United States Pharmacopeia (USP) Reference Standard
EINECS 244-756-1
EU-0100411
FT-0630479
HMS1920I14
HMS2094K15
HMS2234B16
HMS3259J21
HMS3261C04
HMS3369L05
HMS3652M20
HMS501I11
LP00411
LS-130131
MFCD00069254
MLS000028431
MolPort-003-666-169
NC00683
NCGC00093836-01
NCGC00093836-02
NCGC00093836-03
NCGC00093836-04
NCGC00261096-01
Norpace (TN)
Norpace Cr
NSC-756744
NSC756744
O712
Pharmakon1600-01500261
S4143
SAM002264607
SC 13957
SC 7031 phosphate
SC-13957
SCHEMBL41810
SMR000058438
SPECTRUM1500261
SR-01000003039
SR-01000003039-2
SR-01000003039-6
SW196836-3
SW196836-4
Tox21_500411

US Patents and Regulatory Information for NORPACE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc NORPACE disopyramide phosphate CAPSULE;ORAL 017447-001 Approved Prior to Jan 1, 1982 AB RX Yes No   Start Trial   Start Trial   Start Trial
Gd Searle Llc NORPACE CR disopyramide phosphate CAPSULE, EXTENDED RELEASE;ORAL 018655-002 Jul 20, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Gd Searle Llc NORPACE disopyramide phosphate CAPSULE;ORAL 017447-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Gd Searle Llc NORPACE CR disopyramide phosphate CAPSULE, EXTENDED RELEASE;ORAL 018655-001 Jul 20, 1982 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Express Scripts
Dow
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.